αグルコシダーゼ阻害剤の世界市場レポート 2025年

αグルコシダーゼ阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8％で66億1,000万米ドルに成長します。予測期間の成長は、早期介入への重点化、高齢者人口の増加、糖尿病管理のための世界のヘルスケアへの取り組み、併用療法への統合などに起因すると考えられます。予測期間における世界の動向には、患者中心のアプローチ、2型糖尿病管理への注力、ドラッグデリバリーの技術的進歩、新興市場や世界化、提携・パートナーシップなどが含まれます。

糖尿病の世界の有病率の上昇は、α-グルコシダーゼ阻害剤市場の拡大を当面大きく牽引すると予想されます。糖尿病は、血糖値の上昇を特徴とする慢性代謝疾患であり、心臓、血管、目、腎臓、神経を含む様々な身体システムに深刻なリスクをもたらします。α-グルコシダーゼ阻害剤は、小腸における炭水化物の吸収を阻害することによって機能し、食後血糖値の上昇を効果的に抑制し、糖尿病管理に役立ちます。例えば、2022年11月に国際糖尿病連合が発表したデータでは、世界全体で5億3,700万人の成人（10人に1人に相当）が糖尿病に罹患していると報告されています。さらに、予測によれば、世界の糖尿病有病者数は増加し、2030年には6億4,300万人、2045年には7億8,300万人に達すると予想されています。したがって、世界の糖尿病罹患率の増加は、α-グルコシダーゼ阻害剤市場の拡大を促進する重要な要因となっています。

高齢化に向けた人口動態の変化は、α-グルコシダーゼ阻害剤市場の成長を促進する重要なカタリストになると予想されます。高齢化」という用語は、社会や人口集団における高齢者の割合の増加を特徴とする人口動態を意味します。この人口層は、血糖値の調節と管理のためにα-グルコシダーゼ阻害剤を頻繁に利用しています。これらの薬剤は炭水化物の吸収を遅らせる効果があるため、高齢者に多い糖尿病管理を効果的に行うことができます。例えば、2022年10月に世界保健機関（WHO）が発表したデータでは、60歳以上の世界人口の急速な増加が強調されており、2050年までに倍増し、推定21億人に達すると予測されています。その結果、高齢化人口の急増は、α-グルコシダーゼ阻害剤市場の成長を促進する重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界αグルコシダーゼ阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のαグルコシダーゼ阻害剤市場：成長率分析
• 世界のαグルコシダーゼ阻害剤市場の実績：規模と成長, 2019-2024
• 世界のαグルコシダーゼ阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界αグルコシダーゼ阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のαグルコシダーゼ阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ダンピング症候群
• 2型糖尿病
• 世界のαグルコシダーゼ阻害剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アカルボース
• ミグリトール
• ボグリボース
• 世界のαグルコシダーゼ阻害剤市場構成員別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グルコアミラーゼ
• イソマルターゼ
• マルターゼ
• スクラーゼ
• 世界のαグルコシダーゼ阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンライン薬局
• 小売薬局
• 病院薬局
• 世界のαグルコシダーゼ阻害剤市場ダンピング症候群のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胃手術後の管理
• 治療
• 世界のαグルコシダーゼ阻害剤市場2型糖尿病のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単独療法
• 併用療法

第7章 地域別・国別分析

• 世界のαグルコシダーゼ阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のαグルコシダーゼ阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• αグルコシダーゼ阻害剤市場：競合情勢
• αグルコシダーゼ阻害剤市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Alkem Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Emcure Pharmaceuticals Ltd.
• Lupin Ltd.
• Novartis AG
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd.
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• AstraZeneca PLC
• Mitsubishi Tanabe Pharma Corporation
• Eli Lilly and Company
• Johnson & Johnson
• Bristol-Myers Squibb

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• αグルコシダーゼ阻害剤市場2029：新たな機会を提供する国
• αグルコシダーゼ阻害剤市場2029：新たな機会を提供するセグメント
• αグルコシダーゼ阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Alpha-glucosidase inhibitors constitute a class of medications used in diabetes management. They function by impeding the intestine's absorption of carbohydrates, particularly beneficial for individuals with impaired glucose tolerance to prevent the onset of type 2 diabetes mellitus. These inhibitors offer advantages for those at risk of hypoglycemia or lactic acidosis.

The primary applications of alpha-glucosidase inhibitors include addressing dumping syndrome and managing type 2 diabetes. Dumping syndrome encompasses symptoms resulting from swift gastric emptying after meals, leading to a rapid passage of food from the stomach to the duodenum. This acceleration increases sugar levels, and alpha-glucosidase inhibitors play a crucial role in slowing down food digestion, thereby reducing peak blood glucose concentrations post meals. Notable drug classes in this category include acarbose, miglitol, and voglibose, comprising constituents such as glucoamylase, isomaltase, maltase, and sucrase. These medications are distributed through various channels, including online pharmacies, retail pharmacies, and hospital pharmacies.

The alpha-glucosidase inhibitors market research report is one of a series of new reports from The Business Research Company that provides alpha-glucosidase inhibitors market statistics, including alpha-glucosidase inhibitors industry global market size, regional shares, competitors with an alpha-glucosidase inhibitors market share, detailed alpha-glucosidase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the alpha-glucosidase inhibitors industry. This alpha-glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.52 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increased incidence of diabetes, growth in awareness of diabetes management, advancements in diabetes treatment strategies, preference for oral antidiabetic medications, clinical research and evidence-based medicine

The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.61 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing emphasis on early intervention, rising geriatric population, global healthcare initiatives for diabetes control, integration into combination therapies. Major trends in the forecast period include patient-centric approaches, focus on type 2 diabetes management, technological advancements in drug delivery, emerging markets and globalization, collaborations and partnerships.

The escalating global prevalence of diabetes is anticipated to significantly drive the expansion of the alpha-glucosidase inhibitors market in the foreseeable future. Diabetes, a chronic metabolic condition characterized by elevated blood glucose levels, poses severe risks to various bodily systems, including the heart, blood vessels, eyes, kidneys, and nerves. Alpha-glucosidase inhibitors function by impeding carbohydrate absorption in the small intestine, effectively curbing the surge in postprandial blood glucose levels and aiding in diabetes management. For instance, data from the International Diabetes Federation in November 2022 reported that globally, 537 million adults (equating to 1 in 10 individuals) were afflicted by diabetes. Additionally, projections indicate an anticipated increase in global diabetes prevalence, reaching 643 million by 2030 and 783 million by 2045. Hence, the mounting global incidence of diabetes stands as a key driver fueling the expansion of the alpha-glucosidase inhibitors market.

The expanding demographic shift towards an aging population is anticipated to be a significant catalyst propelling the growth of the alpha-glucosidase inhibitors market. The term 'aging population' signifies a demographic trend characterized by an increasing proportion of elderly individuals within a society or populace. This demographic segment frequently utilizes alpha-glucosidase inhibitors to regulate and manage blood glucose levels, as these medications aid in slowing carbohydrate absorption, offering effective diabetes management-a condition prevalent among older individuals. For instance, data from the World Health Organization (WHO) in October 2022 highlighted a swift rise in the global population of individuals aged 60 years and older, projected to double by 2050, reaching an estimated 2.1 billion individuals. Consequently, the burgeoning aging population serves as a significant driver in fostering growth within the alpha-glucosidase inhibitors market.

A burgeoning trend within the alpha-glucosidase inhibitors market revolves around robust product innovation. Major players in this domain are fervently engaged in pioneering novel products to fortify their market stance. A striking example of this trend emerged in January 2023 when TheracosBio, a distinguished pharmaceutical entity based in the United States, garnered approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin). This innovative oral medication operates as an inhibitor of sodium-glucose cotransporter 2 (SGLT2), specifically tailored for adults grappling with type 2 diabetes. Brenzavvy stands as an adjunct to dietary and exercise regimens, functioning by prompting the kidneys to expel sugar through urine, thereby aiding individuals with type 2 diabetes in effectively managing their blood sugar levels.

Strategic product advancements remains a pivotal strategy adopted by major contenders within the alpha-glucosidase inhibitors market. These companies are diligently crafting inventive solutions such as acarbose tablets to fortify their market foothold. Notably, acarbose stands as an established alpha-glucosidase inhibitor instrumental in the management of type-2 diabetes. In March 2022, Shandong Lukang Pharmaceutical Co. Ltd., an esteemed pharmaceutical entity headquartered in China, unveiled its acarbose tablet in the targeted market. Designed to complement dietary control and exercise programs, these tablets offer significant benefits for individuals coping with type 2 diabetes. Furthermore, they aid in curbing postprandial blood glucose levels in patients afflicted with impaired glucose tolerance, serving as a pivotal addition to the array of treatments available for such conditions.

In April 2023, the pharmaceutical company Sanofi S.A., based in France, successfully acquired Provention Bio Inc. for an undisclosed amount. This strategic move is aimed at broadening Sanofi's diabetes drug portfolio by incorporating TZIELD (teplizumab-mzwv), an innovative and fully owned first-in-class therapy designed for type 1 diabetes. Provention Bio Inc., based in the United States, is recognized for its expertise in the development of diabetes drugs.

Major companies operating in the alpha glucosidase inhibitors market include Bayer AG, Merck & Co., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Hanmi Pharmaceuticals Co., Ltd., Eisai Co., Ltd., Biocon Limited, Cadila Pharmaceuticals Ltd

North America was the largest region in the alpha glucosidase inhibitors market in 2024. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha Glucosidase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha glucosidase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha glucosidase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha glucosidase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Dumping Syndrome; Type 2 Diabetes
• 2) By Drug Class: Acarbose; Miglitol; Voglibose
• 3) By Constituent: Glucoamylase; Isomaltase; Maltase; Sucrase
• 4) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospital Pharmacies
• Subsegments:
• 1) By Dumping Syndrome: Post-Gastric Surgery Management; Symptomatic Treatment
• 2) By Type 2 Diabetes: Monotherapy; Combination Therapy
• Companies Mentioned: Bayer AG; Merck & Co.; Alkem Laboratories Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha Glucosidase Inhibitors Market Characteristics

3. Alpha Glucosidase Inhibitors Market Trends And Strategies

4. Alpha Glucosidase Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Alpha Glucosidase Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Alpha Glucosidase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Alpha Glucosidase Inhibitors Market Growth Rate Analysis
• 5.4. Global Alpha Glucosidase Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Alpha Glucosidase Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Alpha Glucosidase Inhibitors Total Addressable Market (TAM)

6. Alpha Glucosidase Inhibitors Market Segmentation

• 6.1. Global Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dumping Syndrome
• Type 2 Diabetes
• 6.2. Global Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acarbose
• Miglitol
• Voglibose
• 6.3. Global Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glucoamylase
• Isomaltase
• Maltase
• Sucrase
• 6.4. Global Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• 6.5. Global Alpha Glucosidase Inhibitors Market, Sub-Segmentation Of Dumping Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Post-Gastric Surgery Management
• Symptomatic Treatment
• 6.6. Global Alpha Glucosidase Inhibitors Market, Sub-Segmentation Of Type 2 Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy

7. Alpha Glucosidase Inhibitors Market Regional And Country Analysis

• 7.1. Global Alpha Glucosidase Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Alpha Glucosidase Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Alpha Glucosidase Inhibitors Market

• 8.1. Asia-Pacific Alpha Glucosidase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Alpha Glucosidase Inhibitors Market

• 9.1. China Alpha Glucosidase Inhibitors Market Overview
• 9.2. China Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Alpha Glucosidase Inhibitors Market

• 10.1. India Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Alpha Glucosidase Inhibitors Market

• 11.1. Japan Alpha Glucosidase Inhibitors Market Overview
• 11.2. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Alpha Glucosidase Inhibitors Market

• 12.1. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Alpha Glucosidase Inhibitors Market

• 13.1. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Alpha Glucosidase Inhibitors Market

• 14.1. South Korea Alpha Glucosidase Inhibitors Market Overview
• 14.2. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Alpha Glucosidase Inhibitors Market

• 15.1. Western Europe Alpha Glucosidase Inhibitors Market Overview
• 15.2. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Alpha Glucosidase Inhibitors Market

• 16.1. UK Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Alpha Glucosidase Inhibitors Market

• 17.1. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Alpha Glucosidase Inhibitors Market

• 18.1. France Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Alpha Glucosidase Inhibitors Market

• 19.1. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Alpha Glucosidase Inhibitors Market

• 20.1. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alpha Glucosidase Inhibitors Market

• 21.1. Eastern Europe Alpha Glucosidase Inhibitors Market Overview
• 21.2. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Alpha Glucosidase Inhibitors Market

• 22.1. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Alpha Glucosidase Inhibitors Market

• 23.1. North America Alpha Glucosidase Inhibitors Market Overview
• 23.2. North America Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Alpha Glucosidase Inhibitors Market

• 24.1. USA Alpha Glucosidase Inhibitors Market Overview
• 24.2. USA Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Alpha Glucosidase Inhibitors Market

• 25.1. Canada Alpha Glucosidase Inhibitors Market Overview
• 25.2. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Alpha Glucosidase Inhibitors Market

• 26.1. South America Alpha Glucosidase Inhibitors Market Overview
• 26.2. South America Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Alpha Glucosidase Inhibitors Market

• 27.1. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Alpha Glucosidase Inhibitors Market

• 28.1. Middle East Alpha Glucosidase Inhibitors Market Overview
• 28.2. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Alpha Glucosidase Inhibitors Market

• 29.1. Africa Alpha Glucosidase Inhibitors Market Overview
• 29.2. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Alpha Glucosidase Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Alpha Glucosidase Inhibitors Market Competitive Landscape
• 30.2. Alpha Glucosidase Inhibitors Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alkem Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Alpha Glucosidase Inhibitors Market Other Major And Innovative Companies

• 31.1. Emcure Pharmaceuticals Ltd.
• 31.2. Lupin Ltd.
• 31.3. Novartis AG
• 31.4. Sanofi SA
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Takeda Pharmaceutical Company
• 31.7. Torrent Pharmaceuticals Ltd.
• 31.8. Unichem Laboratories Ltd.
• 31.9. Pfizer Inc.
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. AstraZeneca PLC
• 31.12. Mitsubishi Tanabe Pharma Corporation
• 31.13. Eli Lilly and Company
• 31.14. Johnson & Johnson
• 31.15. Bristol-Myers Squibb

32. Global Alpha Glucosidase Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alpha Glucosidase Inhibitors Market

34. Recent Developments In The Alpha Glucosidase Inhibitors Market

35. Alpha Glucosidase Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Alpha Glucosidase Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Alpha Glucosidase Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Alpha Glucosidase Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer